Heterocyclic substituted phenyl methanones as inhibitors of the glycine transporter 1

Details for Australian Patent Application No. 2006210047 (hide)

Owner F. Hoffmann-La Roche AG

Inventors Narquizian, Robert; Norcross, Roger David; Jolidon, Synese; Pinard, Emmanuel

Agent Spruson & Ferguson

Pub. Number AU-B-2006210047

PCT Pub. Number WO2006/082001

Priority 05100813.4 07.02.05 EP

Filing date 30 January 2006

Wipo publication date 10 August 2006

Acceptance publication date 3 March 2011

International Classifications

C07D 209/44 (2006.01) Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom

C07D 209/08 (2006.01) Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom

C07D 209/88 (2006.01) Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom

C07D 231/56 (2006.01) Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings

C07D 235/06 (2006.01) Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings

C07D 401/04 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 403/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 405/04 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

C07D 409/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms

C07D 413/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

C07D 417/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

C07D 471/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

C07D 487/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

C07D 491/08 (2006.01) Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or

C07D 498/08 (2006.01) Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms

Event Publications

9 August 2007 PCT application entered the National Phase

  PCT publication WO2006/082001 Priority application(s): WO2006/082001

13 September 2007 Change of Name(s) of Applicant(s), Section 104

  F.Hoffmann-La Roche AG The name of the applicant has been changed to F. Hoffmann-La Roche AG

3 March 2011 Application Accepted

  Published as AU-B-2006210047

30 June 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006210048-Imidazole derivatives

2006210043-Isolation of atraric acid, synthesis of atraric acid derivatives, and use of atraric acid and the derivatives thereof for the treatment of benign prostate hyperplasia, prostate carcinoma, and spinobulbar muscular atrophy